Search

Pseudomonas aeruginosa constitutes one of the opportunistic pathogenic agents with higher frequency of isolation in the different infectious processes; so it is recognized as a great health problem worldwide. As neither a high-effective medicine nor available vaccines exist against this bacterium, a therapy with commercial polyvalent immunoglobulins is used which combined with antibiotics help to eliminate the infection, although preparations available at the market do not contain concentrations of specific antibodies sufficiently high against a certain microorganism. In this work, evaluation of an anti Pseudomonas aeruginosa immunoglobulin for therapeutic use was carried out in an animal model by a challenge assay with a virulent strain. Dose and administration route as well as the prophylactic or therapeutic value of the antibodies were evaluated. This gammaglobulin turned out to be protective in animals showing a survival of about 75?% compared to the non- protected control group. The carrier state can be also eliminated in infected individuals. [ABSTRACT FROM AUTHOR]

The present paper evaluates the toxicity by single dose of the diphtheria-tetanus vaccine (VA-DIFTET®) in Sprague Dawley rats. Its administration was carried out by intramuscular route because this is the one proposed for use in humans. 0.3 mL of the vaccine or its components was administered to a total of 20 animals per group (10 per each sex). These animals were daily observed and, water and food intake was measured on alternate days determining their body weight with week intervals. The anatomopathological analysis of animals was included at the end of the study. No animal died during the assay or clinical symptoms were observed either. No statistically significant differences (p>0,1) were detected regarding water-food intake and body weight. In the anatomopathological study, macrophagic granulomatous lesions were observed in the rats treated with the vaccine or placebo; this finding is characteristic of vaccines adjuvated with aluminum hydroxide. Results suggested that VA-DIFTET® is potentially innocuous when administering the single dose by intramuscular route. [ABSTRACT FROM AUTHOR]